Recent research data surrounding this compound, specifically the 120mg formulation branded as ZPHC, reveal a significant benefit on body mass loss and associated chronic conditions . Scientists posit that this combined agonist , affecting both GLP-1 and GIP systems, has the potential to offer a noteworthy breakthrough in the approach of obesity and